Cogstate (FRA:C4B) Beta: N/A (As of Jun. 24, 2026)


FRA:C4B Cogstate Ltd FRA:C4B
69 GF Score
Price €1.64
GF Value €1.35
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cogstate Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Cogstate's Beta is Not available.


Cogstate  (FRA:C4B) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Cogstate Beta Related Terms


Cogstate Beta Historical Data

* Premium members only.

The historical data trend for Cogstate's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cogstate Beta Chart

Cogstate Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cogstate Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:C4B
69GF Score
Cogstate Ltd FRA:C4B
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cogstate Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Cogstate (FRA:C4B) Overvalued in 2026?

Based on GuruFocus' analysis, Cogstate stock appears to be overvalued. The current stock price of €1.64 is trading 21.5% above its estimated GF Value™ of €1.35. GuruFocus considers Cogstate to be Modestly Overvalued.

Key valuation signals for FRA:C4B:

  • Beta: N/A
  • GF Value™: €1.35 vs. price of €1.64 (21.5% above fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the FRA:C4B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cogstate Business Description

Other Exchanges COGZF:USACGS:Australia
Address 367 Collins Street, Level 32, Melbourne, VIC, AUS, 3000
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
69GF Score

Get the complete analysis for FRA:C4B

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.64
Price
€1.35
GF Value